The Scalability Challenge in MSC Therapies - Top-Institutions - MDSpire

The Scalability Challenge in MSC Therapies

John Yoshi Shyu on why mesenchymal stem cell programs stall – and how early manufacturing decisions can determine clinical and commercial success

  • June 12, 2026

  • 6 min

Share

Top Institutions

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Regenerative Medicine
    • Biomanufacturing

  • #2

    Duke University
    Duke University

    Durham, North Carolina

    Key Differentiators

    • Regenerative Medicine
    • Cellular Therapies

  • #3

    Heinrich Heine University
    Heinrich Heine University

    Düsseldorf, Germany

    Key Differentiators

    • Regenerative Medicine
    • Stem Cell Research

  • #4

    Karolinska Institute
    Karolinska Institute

    Stockholm, Sweden

    Key Differentiators

    • Regenerative Medicine
    • Clinical Research

  • #5

    European Society for Blood and Marrow Transplantation
    European Society for Blood and Marrow Transplantation

    N/A, N/A

    Key Differentiators

    • Transplantation
    • Regenerative Medicine

Original Source(s)

The Scalability Challenge in MSC Therapies

  • June 12, 2026

Related Content

Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?

Testicular Cancer Blood Test Hopes

A newly developed serum immunosignature assay could improve detection of germ cell tumors, including cases missed by conventional tumor markers

  • June 12, 2026

  • 2 min
A multi-method study on GPs’ perspectives on Lipoprotein(a) as an actionable cardiovascular risk factor